Veeva’s Industry Survey Shows 87% of Clinical Operations Leaders Taking Action to Unify Clinical Processes
Over the past year, there has been significant industrywide momentum toward streamlining clinical systems and processes, according to one of the largest annual life sciences surveys of clinical operations professionals from Veeva Systems (NYSE:VEEV).
The latest findings of the Veeva 2018 Unified Clinical Operations Survey reveal that nearly all (99%) clinical leaders surveyed cite the need to unify their clinical environment. Most (87%) report their organizations are taking action with initiatives planned or underway to unify their clinical operations for improved trial performance.
Consistent with the industry’s focus to advance operational performance, many have also made progress modernizing their clinical processes with the adoption of purpose-built applications in key areas. Most notably, the number of organizations that have adopted eTMF applications has quadrupled since 2014, and a majority of respondents (83%) say they have, or plan to have, programs to improve study start-up processes.
End-to-End Visibility, Faster Trial Execution Among Top Needs
Standalone eClinical applications, including EDC, CTMS, and eTMF, are now the norm as sponsors and CROs have steadily adopted function-specific clinical technologies. Application silos are contributing to the industrywide move to unify the clinical operations landscape. Sponsors and CROs say integrating multiple applications (74%) and managing content and data (56%) across them are among the top challenges with their clinical applications.
Findings indicate that disconnected applications hinder the ability to get a full view of clinical trial processes and slow execution. Better visibility and oversight is the primary driver for unifying clinical applications for 77% of respondents, followed by faster study execution (67%) and improved study quality (62%). With a unified clinical environment, organizations can streamline collaboration across study partners and ensure all parties are working within complete end-to-end trial processes.
Consistent use of standardized metrics and KPIs to measure trial performance is one of the greatest areas of opportunity for improving clinical operations. Data shows that those extensively using standardized operational metrics and KPIs report fewer challenges across key trial processes, including study performance metrics and reporting (44% versus 66%, respectively) and visibility into TMF status (32% versus 45%, respectively).
Modernization of Trial Processes Underway
The industry is advancing its processes and systems in major clinical areas such as eTMF and study start-up to impact visibility, collaboration, and compliance, yet significant opportunities remain to further improve efficiency in other operational areas, including CTMS.
Adoption of eTMF has grown significantly and is now the second most commonly used clinical system at 66%. At the same time, the types of eTMFs used has also changed dramatically. Half of sponsors (50%) now have a purpose-built eTMF application versus 13% in 2014. This increase was matched by a sharp decline in the use of general purpose content management systems and file shares. This signals a shift away from passive TMF management toward a mature, active TMF operating model where TMF processes and information are managed in real-time. These active TMF solutions have a positive impact on inspection-readiness and trial performance.
Organizations are also looking at upstream process improvements as an area of significant potential, focusing on study start-up processes and leveraging study start-up applications as major priorities. Top drivers for moving to purpose-built study start-up applications include faster study start-up times (63%), improved site feasibility and site selection outcomes (48%), and better visibility into site performance (44%).
Respondents also cite the need to improve their CTMS as 84% say it is a limiting factor in trial operations. Most have CTMS applications that cannot fully support a range of key functions, including governance and oversight (89%), resource management (88%), and issue and task management (86%). They see improving the CTMS as a way to gain greater visibility (70%), more proactive risk mitigation (65%), and improved study analytics and reporting (61%).
“The life sciences industry sees a significant opportunity to run far more efficient and effective trials,” said Jennifer Goldsmith, senior vice president of Veeva Vault. “As organizations continue down the path toward a unified operating model, trial processes will be transformed for greater visibility and improved trial execution across the clinical lifecycle.”
The Veeva 2018 Unified Clinical Operations Survey examines the life sciences industry’s progress toward a unified clinical environment by gathering the experiences and opinions of 331 clinical operations professionals from around the globe. This research examines the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry’s progress in its move to streamline clinical systems and processes.
For more on Veeva 2018 Unified Clinical Operations Survey, visit: veeva.com/eu/ClinicalSurvey
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 625 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Veeva 2018 Unified Clinical Operations Survey
The Veeva 2018 Unified Clinical Operations Survey examines the life sciences industry’s progress toward a unified clinical environment by gathering the experiences and opinions of 331 clinical operations professionals from around the globe. One of the largest annual life sciences surveys of its kind, this research examines the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry’s progress in its move to streamline clinical systems and processes.
Industrywide Momentum to Unify Clinical Processes
- Nearly all respondents (99%) report the need to unify their clinical trial operating environments, and 87% have or plan to have an initiative underway to unify their clinical operations for improved trial performance.
- The top drivers for unification are to improve visibility and oversight (77%), enable faster study execution (67%), and improve study quality (62%).
- An average of four applications are used to manage their clinical studies, and more than one-third (38%) use at least five applications.
- Integrating multiple applications (74%) is the top challenge resulting from application and process silos, followed by reporting across multiple applications (57%), and managing content and data across applications (56%).
- Clinical applications are now the norm, with EDC (90%), eTMF (66%), RTSM (61%), and CTMS (60%) as the most commonly used applications.
- Those extensively using standardized operational metrics and KPIs to measure clinical trial performance, manage risks, and implement process improvements report fewer challenges across key trial processes, including study performance metrics and reporting (44% versus 66%, respectively) and visibility into TMF status (32% versus 45%, respectively).
- Organizations using metrics are four times more likely to have programs underway to unify their clinical applications than those not using metrics (47% versus 12%, respectively).
Increased Industry Adoption of eTMF Applications
- Half of sponsors now use a purpose-built eTMF application, nearly four times the number since first measured in 2014 (13%).
- The increase in use of purpose-built eTMF applications is matched by a 57% decrease in the use of general-purpose content management systems. This signals a shift away from a passive TMF operating model toward active solutions characterized by the ability to manage TMF processes and information in real-time as the TMF is being generated.
- Organizations’ primary drivers for using purpose-built eTMF applications are improved inspection readiness (70%), better visibility (61%), and improved collaboration across study partners (42%).
Opportunity to Improve Clinical Performance
- Nearly all respondents (99%) cite issues when asked about their most challenging clinical trial management processes, including study performance metrics and reporting (51%), study and site management (49%), and resource management (45%).
- All respondents say they want to improve use of CTMS in their trial operations, with the top drivers being greater visibility (70%), more proactive risk mitigation (65%), and improved study analytics and reporting (61%).
- A majority of respondents (84%) report significant deficiencies with their current CTMS applications, with almost all highlighting the inability to fully support key functions like governance and oversight (89%), resource management (88%), and issue and task management (86%).
Streamlining Study Start-up a Top Priority
- A key finding reveals that streamlining study start-up processes is gaining traction, with 83% of respondents reporting their organizations have a study start-up improvement initiative underway.
- More than half of respondents (53%) report site contract and budgeting among the most challenging study start-up processes that limit their organization’s ability to speed clinical trials, followed by IRB and ethics committee planning and approval (45%), and site identification and selection (41%).
- More than half of respondents (63%) cite faster study start-up times as the primary driver for improving study start-up processes, followed by streamlining site contract and budgeting approval cycles (49%) and improving site feasibility and site selection outcomes (48%).
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Process Systems Enterprise: gPROMS FormulatedProducts 1.4 Includes Enhanced Capabilities Linking Digital Design to Digital Operations19.4.2019 07:58:00 CEST | Pressemelding
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today released version 1.4 of gPROMS FormulatedProducts, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation. This release introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 6.0, including morphological crystallizer and sensor models to capture particle size and shape evolution, enhanced continuous direct compression models and improved wet granulation models. Platform enhancements include support for cluster computing, to significantly speed up execution of parameter estimation and other complex numerical solutions, and comprehensive global system analysis of dynamic systems for rapid exploration of the time-varying decision space and systematic risk and uncertainty analysis. Version 1.4 also introduces two key usability enhan
LOXAM Contributes to the Reconstruction of Notre Dame De Paris Cathedral19.4.2019 07:44:00 CEST | Pressemelding
In the wake of the Notre Dame de Paris blaze on Monday 15 April, Loxam the leading equipment rental company in Europe is playing its part in the reconstruction project of the partly destroyed cathedral. A rental operator in the construction equipment, LOXAM pledges to provide, free of charge, machines to the companies and tradesmen who will take part in these restoration works for the scheduled duration of five years. “Notre Dame de Paris Cathedral is the legacy of accomplished builders that we ought to preserve. As a committed rental operator, Loxam wishes to contribute to the rehabilitation of this monument by providing equipment for an overall 10-million € value over the upcoming five years” Gérard DEPREZ, President of LOXAM, indicates. With a fleet of over 200,000 machines, Loxam is meeting the needs of all tradesmen operating on this worksite. View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005025/en/ Contact information PRESS : Virginie Ada
IFF to Release First Quarter 2019 Results May 618.4.2019 20:15:00 CEST | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its first quarter 2019 earnings results following the market close on Monday, May 6, 2019. The management team will host a live webcast on Tuesday, May 7, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with 97 manufacturing facilities, 105 R&D centers, and 39,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration dri
Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 201918.4.2019 20:05:00 CEST | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 5259422 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, May 4, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID
Andersen Global Expands Africa Presence; Signs Collaboration Agreement in Economic Hub of South Africa18.4.2019 13:30:00 CEST | Pressemelding
Andersen Global is excited to announce the addition of its first collaborating firm in South Africa. Tabacks Attorneys and Corporate Law Advisors, headquartered in Johannesburg, South Africa, has signed a Collaboration Agreement with Andersen Global, an international association of member and collaborating firms. South Africa marks the tenth country in Africa in which Andersen Global has a presence. Led by Chairman David Woodhouse, Tabacks has a team of 27 lawyers who offer legal assistance and commercial advice to a diverse clientele in construction, manufacturing, energy, mining, explosives, retail, hospitality, logistics, pharmaceutical, property and banking industries. The firm is considered a leading law firm in South Africa, and its practice areas include competition law, commercial law, mining, employment law, environmental health & safety law, tax and litigation. “The global economy is rapidly changing, which brings unique challenges to corporate and commercial law,” said David
Amazon and Google Announce Official YouTube Apps to Launch on Fire TV; Prime Video App Coming to Chromecast and Android TV18.4.2019 13:00:00 CEST | Pressemelding
Today, Amazon (NASDAQ: AMZN) and Google (NASDAQ: GOOGL) announced that in the coming months, the two companies will launch the official YouTube app on Amazon Fire TV devices and Fire TV Edition smart TVs, as well as the Prime Video app for streaming to Chromecast and Chromecast built-in devices. In addition, Prime Video will be broadly available across Android TV device partners, and the YouTube TV and YouTube Kids apps will also come to Fire TV later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005212/en/ “We are excited to work with Amazon to launch the official YouTube apps on Fire TV devices worldwide,” said Heather Rivera, Global Head of Product Partnerships at YouTube. “Bringing our flagship YouTube experience to Amazon Fire TV gives our users even more ways to watch the videos and creators they love.” “We’re excited to bring the Prime Video app to Chromecast and Android TV devices, and to give our c